Table 1.

Statistics for the regression analyses of lipid values versus cardiovascular events^a

	Triglycerides		HDL-C		Total cholesterolb		LDL-C
	Slope	P-value	Slope	P-value	Slope	P-value	Slope	P-value
All studies (N=40)	0.488	0.005	0.085	0.822	1.030	<0.001	0.624	<0.001
Population (N=36)c
Primary prevention (N=11)	1.031	0.010	2.251	0.223	1.232	0.044	0.932	0.002
Secondary prevention (N=25)	0.373	0.114	−0.288	0.487	1.264	<0.001	0.507	<0.001
HDL-C level (N=40)
Low (N=20)	0.605	0.013	0.127	0.773	1.294	<0.001	0.539	<0.001
High (N=20)	0.624	0.018	0.719	0.367	0.602	0.041	0.776	<0.001
LDL-C level (N=40)
Low (N=20)	0.765	0.010	0.252	0.625	0.952	<0.001	0.585	<0.001
High (N=20)	0.352	0.136	−0.460	0.497	1.392	<0.001	0.888	<0.001
Total cholesterol level (n=38)b
Low (N=19)	0.765	0.005	−1.575	0.023	0.844	<0.001	0.594	<0.001
High (N=19)	0.456	0.107	−0.455	0.502	1.475	<0.001	1.026	<0.001

Notes:

^aBold font indicates statistical significance at P<0.05

^bJUPITER and AIM-HIGH, which did not report total cholesterol, were omitted from analyses of total cholesterol

^cthe analyses omitted the four trials with mixed primary and secondary populations.

Abbreviations: AIM-HIGH, Atherothrombosis Intervention in Metabolic syndrome with low HDL/High triglycerides: Impact on Global Health outcomes; HDL-C, high-density lipoprotein cholesterol; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol.